Please assess the completion status of the following clinical trial:

Trial Title: Serratus Anterior Plane Block in Patients Undergoing Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients 18 years or older~2. Individuals undergoing either a mastectomy or mastectomy with tissue expander for which the anesthetic plan includes a serratus anterior plane block.~Exclusion Criteria:~1. Any known sensory deficit of the anterolateral chest wall.~2. Any local disorder of the skin or otherwise where blockade is to be performed which would prevent safe performance of the block~3. Pregnancy~4. American Society of Anesthesiology classification greater than 3~5. Allergy to amide local anesthetic medications~6. Chronic pain conditions~7. Preoperative opioid use greater than 20 oral morphine equivalents per day~8. Any coagulation abnormality which would be a contraindication for block placement~9. Preoperative chronic renal dysfunction requiring renal replacement therapy or a serum creatinine greater than 1.4 mg/dL~10. Body mass index \>50~11. Incarceration~12. Inability to understand study procedures including inability to understand the English language~13. Inability to provide adequate informed consent~14. Refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sub-serratus regional block (Type: EXPERIMENTAL): A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
- Supra-serratus regional block (Type: ACTIVE_COMPARATOR): A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.

Based on this trial design, predict the completion outcome and termination type (if applicable).